Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novan Therapeutics
Biotech
Novan crushed by phase 3 failures of antiviral gel
The setback wiped 74% off Novan’s value and left its cash runway looking precariously short, but the biotech plans to start another phase 3.
Nick Paul Taylor
Jan 3, 2020 8:40am
Ex-FDA commissioner joins former Elan team at VC fund
Oct 10, 2017 9:25am
Novan soothes investors with positive antifungal trial
Apr 12, 2017 9:57am
Investors go bargain shopping as Novan IPO prices low, climbs high
Sep 21, 2016 1:41pm
Skin disorder biotech Novan lowers IPO to $45M
Sep 9, 2016 4:13am
